Licensing, Acquisitions, and Other Arrangements - Acquisition of Allergan (Details) - USD ($) $ / shares in Units, $ in Millions			6 Months Ended	8 Months Ended	12 Months Ended
		May 08, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition
Closing price of AbbVie common stock (in dollars per share)	[1]	$ 83.96
Goodwill measurement period adjustments	[2]				$ 564
Amortization of intangible assets					7,718	$ 5,805	$ 1,553
Fair Value of Assets Acquired and Liabilities Assumed
Goodwill				$ 33,124	32,379	33,124	15,604
Allergan plc
Business Acquisition
Cash per share received by Allergan shareholders (in dollars per share)	[3]	$ 120.30
Amount of AbbVie stock per share received by Allergan shareholders (in shares)	[1]	0.8660
Allergan ordinary shares outstanding at closing (in shares)	[3]	330,000,000
Shares of AbbVie's common stock issued to Allergan shareholders (in shares)	[1]	286,000,000
Stock options issued to Allergan's equity award holders (in shares)	[4]	11,200,000
RSUs issued to Allergan equity award holders	[4]	8,200,000
Other net measurement period adjustments to identifiable net assets			$ 2
Goodwill measurement period adjustments			564
Fair value step-up adjustment to inventories		$ 1,200
Weighted average useful life of acquired intangible assets				12 years
Fair value of purchase price adjustment to long-term debt		1,300
Net revenues attributable to Allergan from acquisition date				$ 10,300
Operating losses attributable to Allergan from acquisition date				1,100
Amortization of intangible assets				4,000
Inventory fair value step-up amortization				$ 1,200
Consideration Transferred
Cash consideration paid to Allergan shareholders	[3]	39,675
Fair value of AbbVie common stock issued to Allergan shareholders	[1]	23,979
Fair value of AbbVie equity stock issued to Allergan equity award holders	[4]	430
Total consideration		64,084
Fair Value of Assets Acquired and Liabilities Assumed
Cash and equivalents		1,537
Short-term investments		1,421
Accounts receivable		2,374
Inventories		2,340
Prepaid expenses and other current assets		1,982
Investments		137
Property and equipment		2,129
Intangible assets - Developed product rights		68,190
Intangible assets - In-process research and development		1,600
Other noncurrent assets		1,395
Short-term borrowings		(60)
Current portion of long-term debt and finance lease obligations		(1,899)
Accounts payable and accrued liabilities		(5,852)
Long-term debt and finance lease obligations		(18,937)
Deferred income taxes		(3,940)
Other long-term liabilities		(4,765)
Total identifiable net assets		47,652
Goodwill		16,432
Total assets acquired and liabilities assumed		$ 64,084
Pro Forma Information
Net revenues						50,521	49,028
Net earnings (loss)						6,746	(38)
Allergan plc | Developed product rights intangible assets
Business Acquisition
Intangible assets measurement period adjustments			710
Allergan plc | IPR&D intangible assets
Business Acquisition
Deferred income tax measurement period adjustment			$ (148)
Allergan plc | Selling, general and administrative
Business Acquisition
Acquisition-related expenses					$ (401)	$ 781	$ 103

[1] Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for each outstanding Allergan ordinary share at the May 8, 2020 closing price of $83.96 per share.

[2] Measurement period adjustments recorded in 2021 related to the acquisition of Allergan (see Note 5).

[3] Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing.

[4] Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.